Skip to main content
. 2019 Mar 3;33(2):611–619. doi: 10.21873/invivo.11518

Figure 2. Impact of del(17p13) on progression free survival (PFS). (A) PFS of del(17p13) patients compared to those without. (B) Impact of del(17p13) on PFS in ISS stage I/II patients. (C) Impact of del(17p13) on PFS in ISS stage III patients.

Figure 2

Figure 2